Update on thyroid eye disease and management

Erick D Bothun,1,2 Ryan A Scheurer3 Andrew R Harrison,1,3 Michael S Lee1,4,5
1 Departments of Ophthalmology, 2 Pediatrics, 3 Otolaryngology, 4 Neurosurgery, and 5 Neurology, University of Minnesota, Minneapolis, Minnesota, USA

Abstract: Thyroid eye disease is a heterogeneous autoimmune orbital reaction typically manifesting in middle age. The inflammation may parallel or remain isolated from a related inflammatory cascade in the thyroid called Graves’ disease. The orbital manifestations can lead to severe proptosis, dry eyes, strabismus, and optic neuropathy. In this article, we will discuss this unique condition including the ophthalmic findings and management.

Keywords: Graves’ disease, thyroid eye disease, proptosis, orbital decompression, enlarged extraocular muscles

Pathogenesis and epidemiology
The overwhelming majority (90%) of thyroid eye disease (TED) cases are associated with hyperthyroidism, while the rest are either euthyroid or hypothyroid.1 Cross-reactivity against shared antigen(s) in thyroid and orbital tissue is most likely responsible for the autoimmune ophthalmologic reaction. Antibodies involving the thyroid-stimulating hormone (TSH) receptor may drive the pathogenesis of this inflammation.2 Autoreactive T lymphocytes migrate into the orbital soft tissue, fat and musculature reacting with the shared thyroid and orbital antigen(s). The inflammation results in anatomical changes including eyelid retraction (NOSPECS class I) and redness and swelling of periorbital tissues (class II) including the eyelids, conjunctiva, and caruncle.3,4 Secretion of a cytokine cascade stimulates fibroblast proliferation and secretion of glycosaminoglycans resulting in proptosis (class III) from retro-orbital fat expansion and extraocular muscle swelling. The expansion of orbital tissues may lead to the severe motility disorders (class IV), corneal exposure (class V) and optic nerve damage (class VI). Eventually this process results in fibrosis of the extraocular musculature and permanent restriction of eye and lid movements.

Both endogenous (genetic factors, increased age, male sex) and exogenous factors (smoking, thyroid dysfunction, and radioiodine treatment) likely contribute to the development or severity of TED.5,6 Approximately half of Graves’ disease patients experience ophthalmic manifestations, with sight-threatening disease in 3% to 5% of cases.7 The heterogeneous manifestations and variable course of TED may greatly affect the quality of life in affected patients.

Although TED is a heterogeneous genetic disorder, finding a common genetic loci remains elusive. Candidate genes include human leukocyte antigen (HLA, 6p21–3), cytotoxic T-lymphocyte antigen-4 (CTLA-4, 2q33), tumor necrosis factor (TNF, 6p21–3), interferon-γ, 12q14), intercellular adhesion molecule-1 (ICAM-1, 19p13), and thyroid...
stimulating hormone receptor gene (TSH-R, 14q13). TED exhibits a female to male ratio of 4:1; however, more severe disease occurs among affected elderly males.

**Course of disease**

Thyroid eye disease typically has an inflammatory, active phase subsiding over one to two years (range 6 months to 5 years) into a fibrotic, inactive phase (Figure 1). After the inflammation subsides, patients may suffer permanent structural changes around the eyes requiring treatment. Active inflammation recurs in about 1% of patients after months to years of inactivity. Unfortunately, no reliable test or sign exists to determine when the inactive phase has begun. These patients return for repeat evaluations to document changes in symptoms or clinical findings. Stable clinical findings for 6 months suggest that the patient has passed from the active to the inactive phase. It is important to recognize every patient’s course of TED is different and unique. Some may have minimal signs while others have sudden onset of severe complications such as severe diplopia, proptosis and vision loss.

Smoking has a strong relationship with the course and severity of thyroid eye disease. The relationship is dose-responsive between cigarette use and probability of developing thyroid eye disease. Smoking is associated with an increased risk of ophthalmic disease after radioiodine therapy and worse thyroid eye disease.

The earliest findings in TED usually involve mild soft tissue inflammation. Early symptoms include foreign body sensation, excessive tearing from dry eye, conjunctival or eyelid redness and swelling, blurred vision, and retro-orbital pain. Dilated conjunctival vasculature, keratoconjunctivitis, and corneal staining may be seen on slit lamp examination.

As the orbital inflammation progresses in severity, swelling of the extraocular muscles (EOM) or orbital soft tissue often manifests as chemosis, lid edema and ocular proptosis. The EOM may become visible as blood vessels over their anterior portion show prominence. Such vessel engorgement overlying the lateral rectus has been described as a sign of activity; however this may persist during the inactive disease phase. Poor venous drainage secondary to the congestive mass effect behind the eyes may contribute to redness and swelling of the eyelids, conjunctiva, and caruncle. Involvement of the levator palpebrae results in eyelid retraction and the characteristic “stare” of TED (Figure 2). This appearance is often exaggerated by the presence of exophthalmos. Progressive proptosis with eyelid retraction and meibomian gland inflammation may worsen corneal exposure and progress to corneal ulceration and perforation. Inflammation and scarring of the EOM can cause strabismus and ophthalmoplegia. In mild cases, patients might feel a pulling sensation around the eyes. With more advanced disease, horizontal, vertical and torsional strabismus and double vision ensue (Figure 3). Asymmetric EOM restriction manifests as incomitant deviations with diplopia in eccentric gazes, ie, sidegaze esotropia or upgaze hypotropia with medial or inferior involvement respectively. In severe cases the restrictive, incomitant strabismus occurs in primary gaze and patients complain of constant double vision. In addition to vertical and torsional tropias, inferior rectus involvement may lead to a poor Bell’s phenomenon with increased risk of corneal exposure. Diffuse orbital and EOM restriction may lead to intermittent spiking or chronic elevation of intraocular pressure. Intraocular pressures should regularly be tested in both primary and upgaze. Strabismus may develop at any stage in the disease or secondary to orbital changes after decompression surgery. In addition,
vertical rectus strabismus surgery may cause iatrogenic eyelid retraction and worsen corneal exposure.

With severe inflammation, the expansion of soft tissues confined within the bony orbit and swelling of the muscles at the apex of the orbit may compress the optic nerve causing dysthyroid optic neuropathy (Figure 4). Although early symptoms include progressive blurring of vision and fading of colors in one or both eyes, visual acuity may be preserved in a minority of patients with optic neuropathy. Of note, when optic neuropathy occurs the degree of proptosis often does not correlate. Presumably, this occurs when the enlarged EOM expand to compress the optic nerve instead of producing exophthalmos. Signs of optic neuropathy include decrease in visual acuity, visual field, and color vision along with the development of an afferent pupillary defect. Bilateral, simultaneous optic neuropathy can occur which would eliminate a relative afferent pupillary defect. The optic disc may be normal or edematous. Without detection through serial screenings and subsequent prompt treatment, permanent optic atrophy and visual loss may occur.

Careful evaluation of TED patients presenting to an ophthalmologist allows for quantitative assessment disease activity and severity. Activity of thyroid eye disease can be assessed with the Clinical Activity Score (Table 2). The clinical features of inflammation are graded based upon comparison with photographs to improve objectivity. Severity may be assessed using the NOSPECS classification; this mnemonic for evaluation assists in differentiation of mild, moderate, and severe disease (Table 1). Impairment of quality of life can be elicited with the Graves’-ophthalmopathy specific QOL questionnaire (GO-QoL). Initial laboratory studies include bloodwork for thyroid stimulating hormone (TSH), thyroid stimulating immunoglobulin (TSIG), thyroid peroxidase (TPO) antibody, and TSH receptor antibody.

Lastly, radiographic imaging using CT, MRI, or ultrasound may aid in the diagnosis of thyroid eye disease. CT scanning is the modality of choice to evaluate dysthyroid optic neuropathy and the planning of surgical intervention. Findings often include enlargement of orbital fat or musculature with sparing of insertions. The inferior and medial recti are most commonly affected. Other finding on imaging include intracranial prolapse of fat through the superior orbital fissure, straightening of the optic nerve or impingement of apical musculature on the optic nerve.

The differential diagnosis for the clinical features of thyroid eye disease includes infectious and inflammary orbital conditions such as orbital myositis, idiopathic orbital inflammatory syndrome, and orbital cellulitis. Rarer conditions include orbital neoplasms and carotid artery – cavernous sinus fistulas. New onset diplopia may result from cranial nerve palsies, internuclear ophthalmoplegia, or myasthenia gravis.

Management Patients with Graves’ ophthalmopathy should be managed by a coordinated team of primary care physicians,
endocrinologists, and ophthalmologists with specialty experience in managing TED. This typically involves a neuro-ophthalmologist, an orbital surgeon, and a strabismus surgeon. The complicated nature of treatment often requires coordination of medical, surgical and radiation therapy. Uncontrolled thyroid function is associated with more severe thyroid eye disease. However, antithyroid drugs and surgical subtotal/near-total thyroidectomy therapies typically do not improve the ophthalmic disease course. In fact, radioiodine therapy for Graves’ disease can exacerbate ocular disease; particularly in the context of smoking, active disease, or elevated TSH-receptor autoantibodies. Administration of steroids during and following radioiodine therapy decreases the risk of exacerbation in patients with active TED. When radioiodine is administered to patients with inactive TED, risk of eye disease exacerbation is minimal.

Ophthalmologic treatment must be tailored to the patient’s quality of life, psycho-social effects, and severity and stage of disease. Smoking cessation is mandatory in all phases because it worsens outcome and represents a modifiable risk factor. Mild, early disease does not require surgical or immunomodulating therapy and clinicians may choose to wait and monitor signs. Management can be symptomatic with lubricating eye drops and ointments for corneal exposure and temporary prisms for diplopia. Serial examinations are necessary to screen for progression of disease and determination of stability. Moderately severe or severe worsening of orbital congestion and/or severe proptosis can occur with concurrent dysthyroid disease or many years after well-controlled thyroid function from Graves’ disease. When sight is threatened from optic neuropathy or corneal breakdown, urgent referral is necessary to initiate “rescue” therapy, often with glucocorticoid administration and/or orbital decompression. Once the chronic inflammation associated with TED becomes quiescent and a period of stability is noted, “rehabilitative” surgical therapies may be considered.

**Rescue therapy**

When moderate to severe TED is present, early “rescue” intervention may be indicated. Indications for “rescue” include evidence of optic neuropathy, significant proptosis and extensive exposure keratopathy. Urgent “rescue” treatment, either alone or a combination, includes corticosteroids, surgical orbital decompression, and orbital radiation.

Severe thyroid eye disease is often treated initially with glucocorticoids. The efficacy and tolerability of intravenous administration (IV) is superior to oral or local injection. Oral glucocorticoids, typically prednisone 60 to 100 mg/day, must be taken over an extended period of time. With oral glucocorticoids, bisphosphonates should be considered.

### Table 1 Clinical activity or severity may be assessed with either the Clinical Activity Score (CAS) or the NOSPECS severity assessment

<table>
<thead>
<tr>
<th>Clinical Activity Score (CAS)</th>
<th>NOSPECS Severity Assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Score determined by sum of the symptoms and signs in a patient with TED a given visit</td>
<td>No signs or symptoms</td>
</tr>
<tr>
<td>Spontaneous retrobulbar pain</td>
<td>Lid aperture (mm)</td>
</tr>
<tr>
<td>Pain on attempted up-gaze or down-gaze</td>
<td>Only signs, no symptoms</td>
</tr>
<tr>
<td>Redness of the eyelids</td>
<td>Swelling, redness</td>
</tr>
<tr>
<td>Redness of the conjunctiva</td>
<td>Soft tissue involvement</td>
</tr>
<tr>
<td>Swelling of the eyelids</td>
<td>Proposis</td>
</tr>
<tr>
<td>Inflammation of the caruncle and/or plica</td>
<td>Exophthalmos (mm)</td>
</tr>
<tr>
<td>Edema of the conjunctiva</td>
<td>Extraocular muscle involvement</td>
</tr>
<tr>
<td><strong>Class 0</strong></td>
<td>Ductions (degrees), diplopia score (0, no diplopia; 1, intermittent; diplopia in primary position of gaze when tired or awake; 2, inconstant; diplopia at extremes of gaze; 3, constant; diplopia always present)</td>
</tr>
<tr>
<td><strong>Class 1</strong></td>
<td>Corneal involvement</td>
</tr>
<tr>
<td><strong>Class 2</strong></td>
<td>Sight involvement</td>
</tr>
<tr>
<td><strong>Class 3</strong></td>
<td>Punctate keratopathy, ulceration</td>
</tr>
<tr>
<td><strong>Class 4</strong></td>
<td>Optic nerve involvement; changes in visual acuity, color vision, visual fields, or optic disk</td>
</tr>
</tbody>
</table>

**Table 1.** Clinical activity or severity may be assessed with either the Clinical Activity Score (CAS) or the NOSPECS severity assessment.
limited. Botulinum administration to the levator complex has been shown to temporarily improve lid retraction and corneal exposure.\textsuperscript{47}

The data surrounding use of external ionizing orbital radiation is mixed. Clinical application of such therapy for dysthyroid optic neuropathy lacks conclusive support. Orbital radiation in the active disease phase showed no efficacy in one report.\textsuperscript{48} Radiation is equally as effective as oral glucocorticoids,\textsuperscript{49} yet the combination of treatments provide better results than either individual therapy.\textsuperscript{50} In trials approximately 60% of patients respond to radiation.\textsuperscript{51} A recent report reviewing orbital radiation found improvement in extraocular motility; however, no evidence of improvement in proptosis, eyelid retraction, or soft tissue swelling.\textsuperscript{52} Lower doses of radiation, 1 Gy per week for 20 weeks, have been shown to be equally effective and better tolerated than higher doses, 20 Gy per orbit over 2 weeks.\textsuperscript{53,54} Safety of orbital radiation is encouraging; new onset of definite radiation retinopathy is 1% to 2% over 10 years.\textsuperscript{55} Absolute contraindications include diabetic retinopathy and severe hypertension, while young age represents a relative contraindication.\textsuperscript{56} Fortunately, radiation therapy does not appear to compromise future surgical therapies.\textsuperscript{57}

Rehabilitative surgical therapy, as described below, is best initiated after six months of stable, inactive thyroid eye disease.\textsuperscript{58} If decompression surgery is performed in the active phase, additional decompression may be necessary due to inflammatory changes that persist post-operatively. Additionally, spontaneous remission of symptoms is possible with resolution of the active phase. Wise timing could, therefore, spare patients from unnecessary procedures.

**Rehabilitative surgical therapy**

Rehabilitative surgical therapies are implemented for stable, inactive TED. Such surgical therapy typically involves orbital decompression, strabismus surgery, eyelid repositioning and blepharoplasty. Patients with mild disease may only require one of these restorative procedures. Conversely, patients with severe disease may require all three types of surgery in succession as needed. The order of these procedures is important because decompression may alter or create strabismus, and strabismus surgery on vertical recti can alter eyelid positioning.

**Orbital decompression surgery**

Traditional indications for decompression involved predominantly optic neuropathy and severe exposure keratopathy. Currently medical therapy including external beam radiotherapy may be considered prior to decompression.
for optic neuropathy. Proptosis has expanded as a surgical indication to include decompression for cosmesis; and decompression is often utilized to provide relief of congestion. Orbital decompression involves either removal of or thinning of any combination of orbital wall surfaces in addition to removal of orbital fat. In bony decompression, additional space is created for soft tissues to prolapse, often into the ethmoid or maxillary sinuses, temporal fossa, and/or cranial cavity. Removal of the inferior wall with the medial, inferomedial and lateral, balanced medial and lateral, and deep lateral wall decompression are common techniques. Alteration of the orbital vault structure can lead to new onset of diplopia. In patients lacking diplopia before surgery a medial and lateral balanced decompression has been advocated. The objective of this technique is to decrease morbidity including hypoglosus and imbalanced motility. Endoscopic medial and external lateral technique has been shown to provide effective orbital decompression and compares favorably to 3-wall decompression.

Deep lateral wall decompression has reportedly reduced proptosis as much as 6 mm. (Figures 5, 6) Lateral wall decompression alone has a low rate of new onset diplopia of approximately 7%, with reports as low as 2.6%. Complications of deep lateral decompression include cerebrospinal fluid leaks. A volume expansion of 5.6 cc may be achieved with this procedure alone. Deep lateral decompression may also be combined with removal of other walls as needed.

Fat decompression
Removal of intraconal fat reduces congestive orbitopathy, proptosis, and may improve preoperative diplopia. Selection of patients is important and CT or MRI is useful in assessing those with predominantly fatty or muscular soft tissue enlargement. Patients with orbital fat expansion experience better outcomes from fat-only decompression than patients with predominantly extraocular muscle enlargement. Decompression typically involves the inferolateral and superomedial compartments with removal of 3–6 cc of intraconal fat. Safety has been verified with proper selection of patients with orbital fat volume expansion, and new onset diplopia is rare. Intraconal fat debulking may be utilized alone or in combination with bony decompression.

Strabismus
Thyroid eye disease patients often develop diplopia and strabismus requiring surgical correction. The restrictions in motility are most commonly hypotropia or esotropia caused...
by inferior and medial rectus involvement respectively. Strabismus may present with the onset of orbitopathy or as a direct result of decompression surgery. Patients with preoperative diplopia undergoing inferior and medial wall decompression may experience worsening.\(^{53}\) Surgical correction of strabismus is, therefore, planned after decompression. The primary goal of strabismus surgery in TED is restoration of single binocular vision in primary gaze and reading position. (Figures 7, 8) Managing patient expectations is important and the surgeon should counsel that single binocular vision in all fields may not be possible. Resection of extraocular muscles is rarely recommended due to the fibrosis and restriction of musculature. Muscle recession on adjustable sutures are frequently utilized since results are more unpredictable compared to the pediatric population.\(^{64}\) A single surgery functions sufficiently in 85% of cases with reoperation or prism use in the remainder.\(^{65}\) Approximately 25% of all TED patients use prisms or adopt an abnormal head positioning after surgery.

**Eyelid repositioning and blepharoplasty**

Surgery for lengthening eyelids and reducing retraction is frequently performed for patients. Benefits include improvement in symptoms of corneal exposure and appearance. Eyelid repositioning should take place after orbital decompression and strabismus surgeries since vertical rectus surgery may alter eyelid position.\(^{66}\) (Figures 9, 10) Patients with TED often develop significant fatty prolapse and dermatochalasis of the eyelids requiring blepharoplasty. This procedure may be performed in concert with eyelid repositioning, but often is performed later as a separate procedure.

**Future therapies**

Controversial therapies include a variety of other immunomodulatory agents. Cyclosporine has been shown to work synergistically when used with glucocorticoids.\(^{67}\) Other research suggests that agents including rituximab and etanercept may be beneficial.\(^{68,69}\) Agents with less proven value include azathioprine, cimeneux, iv immunoglobulin, and somatostatin analogs. There is hope for future use of therapies targeting the immune system and the pathophysiologic mechanism of thyroid eye disease, however, no conclusive data yet exists.

**Summary**

Patients with thyroid eye disease necessitate serial examinations and at times intensive specialty care for the ocular manifestations of this disfiguring and potentially blinding disorder. At the University of Minnesota such care is orchestrated by the Center for Thyroid Eye Disease where patients are cared for at each clinical visit by a neuro-ophthalmologist, orbital and oculoplastic surgeon, and strabismologist. Through this multispecialty approach, the patient’s strategic management and outcome are maximized.

**Acknowledgments**

Supported, in part, by an unrestricted Departmental grant from Research to Prevent Blindness, Inc., New York, NY, USA.

**Disclosures**

The authors disclose no conflicts of interest.

**References**


